Ally Bridge Group
PE / VC · New York · United States
Stages
Investment region
Industries
Profile
Ally Bridge Group is a global healthcare investment management firm that focuses on high-impact life science innovation. Founded in 2013 by Frank Yu, who serves as the Chief Executive Officer and Chief Investment Officer, the firm operates from offices in New York and Hong Kong. With a team that combines deep scientific knowledge with expertise in mergers and acquisitions, Ally Bridge Group aims to generate superior risk-adjusted returns while addressing unmet medical needs. The firm invests across the global healthcare industry, utilizing both private equity and public equity strategies. Their investments span various healthcare subsectors, and they seek to deliver returns through a comprehensive understanding of value in both private and public markets. Ally Bridge Group has been involved in over $6 billion of transactions since its inception, showcasing its commitment to impactful investments in the life sciences sector. Notable investments include Medtronic - medical technology leader, Intercept Pharmaceuticals - biotech innovator, and various companies in the medical devices and digital health sectors. The firm's approach emphasizes synergies between private and public equity platforms, leveraging global insights to secure opportunities in life science innovation.
Contacts (2)
| Name | Title | Phone | ||
|---|---|---|---|---|
| Partner and Managing Director, Head of Private Equity | — | — | — | |
| Vice President, Biotech Private Equity | — | — | — |
Name, email and phone are partially hidden. Subscribe to see them in full.